Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA

Correspondence to: S M Hanash, Department of Pediatarics, University of Michigan, 1150 W Medical Center Drive, MSRBI, Room A520, Ann Arbor, MI 48109, USA; Fax: 734 647 8148

Although most drugs target proteins, the proteome has remained largely untapped for the discovery of drug targets. The sequencing of the human genome has had a tremendous impact on proteomics and has provided a framework for protein identification. There is currently substantial interest in implementing proteomics platforms for drug target discovery. Although the field is still in the early stages, current proteomic tools include a variety of technologies that could be implemented for large-scale protein expression analysis of cells and tissues, leading to discovery of novel drug targets. Proteomics uniquely allows delineation of global changes in protein expression patterns resulting from transcriptional and post-transcriptional control, post-translational modifications and shifts in proteins between different cellular compartments. Some of the current technologies for proteome profiling and the application of proteomics to the analysis of leukemias by our group are reviewed.

Leukemia (2002) 16, 478-485. DOI: 10.1038/sj/leu/2402412

proteomics; cancer; microarray; Op18; therapeutics